Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Marvell Technology Inc (MRVL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Marvell Technology Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Marvell Technology Inc trades at $228.53 (market cap $206.99B). The key difference: Marvell Technology Inc is far larger — about 5.2× Alnylam Pharmaceuticals, Inc.'s market cap, and Marvell Technology Inc pays a 0.1% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | MRVL | |
|---|---|---|
Market Cap | $39.89B | $206.99B |
Sector | Health | Technology |
52-Week High | $491.22 | $316.43 |
52-Week Low | $278.09 | $62.31 |
Enterprise Value | $38.15B | $208.42B |
Dividend Yield | — | 0.1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Marvell Technology (MRVL) trades at $235.81, down 3.07% on the day, with a neutral technical signal despite bullish moving averages. The company shows strong profitability margins but elevated valuation ratios, with a P/E of 81.03. Recent quarters have consistently beaten EPS estimates, and analyst consensus is overwhelmingly bullish with an 82.19% buy rating and a $275 price target. Cash flow trends indicate improving operational performance, though net income has been negative historically, with a projected turnaround to $2.5B net profit in 2026.
The outlook for MRVL is positive, driven by AI infrastructure growth engines and a strategic partnership with Nvidia, positioning it for significant revenue expansion. Risks include high valuation multiples, competitive pressures in the semiconductor space, and reliance on continued AI investment. The stock presents a growth opportunity if execution matches guidance, but investors should be cautious of volatility and earnings sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Marvell Technology Inc
Marvell Technology is a leading fabless chipmaker focused on networking and storage applications. Marvell serves the data center, carrier, enterprise, automotive, and consumer end markets with processors, optical interconnections, application-specific integrated circuits (ASICs), and merchant silicon for Ethernet applications. The firm is an active acquirer, with five large acquisitions since 2017 helping it pivot out of legacy consumer applications to focus on the cloud and 5G markets.
Read more on MRVL →
